1、2025Innovating For A Global FutureSCRIP ASIA 100 3 Copyright 2024 Pharma Intelligence UK Limited(Citeline),a Norstella company(Unauthorized photocopying prohibited)2 SCRIP ASIA 100Copyright 2024 Pharma Intelligence UK Limited(Citeline),a Norstella company(Unauthorized photocopying prohibited)In-pers

2、on attendance at conferences and exhibitions across the Asia-Pacific region seems to be exceeding pre-pandemic levels,marking a robust rebound in business travel and a surge in tourism,especially in Japan.While signs of post-COVID normalization are evident,the biopharma sector in the region has cont

3、inued to be characterized over the past year by a complex mix of factors some a hangover from the pandemic and others emerging independently.Despite some improvement,lingering investor uncertainties continued to dominate the fundraising environment in China and South Korea,where few IPOs have occurr

4、ed this year.This partly reflects wider macroeconomic factors,and heightened investor expectations following the coronavirus bonanza.Long-simmering geopolitical tensions,notably between the US and China,have solidified with the planned US BIOSECURE Act,which casts a large shadow over business intera

5、ctions and threatens the operations of targeted Chinese firms in the US.Meanwhile,several major Japanese firms are cutting thousands of jobs precipitated by various company-specific factors such as major patent expirations and pipeline reprioritizations.Yet a reimbursement pricing environment long c

6、riticized for lacking incentive may have contributed,with prices continuing to be cut in regular revisions based on cost-effectiveness and sales expansion.Chinas general economic slowdown,along with ongoing challenges around reimbursement,formulary inclusion and price pressure,is scrubbing off some